华仁药业(300110) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥302,160,742.94, a decrease of 21.90% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥22,317,908.63, down 59.28% year-over-year[2] - The net profit after deducting non-recurring gains and losses was ¥22,167,480.93, reflecting a 56.84% decline compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 1,073,621,963.53, a decrease of 11.7% compared to CNY 1,215,927,751.99 in the same period last year[18] - Net profit for Q3 2024 was CNY 100,471,124.16, a decline of 28.6% compared to CNY 140,650,990.51 in Q3 2023[19] - The total comprehensive income for the third quarter was approximately CNY 100.47 million, a decrease from CNY 140.65 million in the previous year, representing a decline of about 28.6%[20] Assets and Liabilities - The total assets as of September 30, 2024, were ¥4,872,661,455.24, a decrease of 5.67% from the end of the previous year[2] - The company's total assets decreased to CNY 4,872,661,455.24 from CNY 5,165,697,057.91, reflecting a reduction of 5.7%[17] - Current liabilities totaled CNY 1,424,136,105.82, down 6.1% from CNY 1,516,260,018.04 in the previous year[16] - The company's total liabilities decreased by 5.67% compared to the previous year, with short-term borrowings down by 32.77%[5] - Long-term borrowings decreased to CNY 566,680,000.00 from CNY 836,420,000.00, a decline of 32.2%[16] Cash Flow - The company's cash flow from operating activities for the first nine months of 2024 was ¥285,386,815.04, an increase of 44.82% year-over-year[2] - Cash flow from operating activities generated CNY 1.22 billion, compared to CNY 1.38 billion in the previous year, indicating a decline of about 11.5%[21] - Net cash flow from operating activities was CNY 285.39 million, an increase from CNY 197.06 million year-over-year, showing a growth of approximately 44.7%[22] - Cash outflow from investing activities was CNY 37.31 million, down from CNY 95.58 million in the previous year, representing a decrease of about 61.0%[22] - Cash flow from financing activities resulted in a net outflow of CNY 360.27 million, compared to a net outflow of CNY 102.15 million in the previous year, indicating a significant increase in outflow[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,396[9] - The largest shareholder, Xi'an Qujiang Tianshu Great Health Investment Partnership, holds 20.00% of the shares, totaling 118,221,298 shares[10] - The top ten shareholders hold a significant portion of the shares, with the top three alone accounting for over 34%[10] - The company has not disclosed any related party relationships among the top shareholders[10] Research and Development - Research and development expenses for Q3 2024 were CNY 49,578,277.19, an increase of 14.7% compared to CNY 43,426,283.82 in Q3 2023[18] - The company obtained four Class II medical device registration certificates during the reporting period[13] - The company’s subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., received a drug registration certificate for ketamine injection, which is considered to have passed the consistency evaluation[13] - The company’s subsidiary also received approval for the market application of ketamine raw materials and papaverine hydrochloride raw materials[13] Inventory and Receivables - Accounts receivable decreased to ¥583,566,052.09 from ¥654,726,627.36[14] - Other receivables increased slightly to ¥1,369,964,879.32 from ¥1,364,138,561.77[14] - The company's inventory decreased to CNY 310,685,070.75 from CNY 334,628,729.51, a reduction of 7.1%[15] Earnings Per Share - The basic earnings per share for Q3 2024 were ¥0.0189, down 59.31% compared to the same period last year[2] - Basic and diluted earnings per share for the quarter were CNY 0.0808, down from CNY 0.1160 in the same period last year, reflecting a decrease of approximately 30.3%[20]